Endologix (ELGX) Misses Q1 EPS by 5c

Endologix (NASDAQ: ELGX) reported Q1 EPS of ($0.26), $0.05 worse than the analyst estimate of ($0.21). Revenue for the quarter came in at $42.6 million versus the consensus estimate of $41.11 million.

Financial Guidance

Endologix reaffirms its previously issued revenue guidance and continues to anticipate 2017 revenue to be in the range of $193 million to $200 million, representing reported growth of 0% to 4% and constant currency growth of 2% to 5% compared to 2016. Endologix now anticipates 2017 GAAP loss per share of $(0.83) to $(0.86), compared to its prior guidance of a GAAP loss per share of $(0.70) to $(0.76). This revised guidance primarily reflects increased interest expense and debt extinguishment related charges.

For earnings history and earnings-related data on Endologix (ELGX) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c
• SanDisk upgraded at JPMorgan after investor day; shares climb